AdipoGen Life Sciences

anti-LAG-3 (human), mAb (17B4) (ATTO 590)

CHF 490.00

In stock

AG-20B-0012TM-T100100 testsCHF 490.00

More Information
Product Details
Synonyms	Lymphocyte Activation Gene-3; FDC Protein; CD223
Product Type	Monoclonal Antibody
Properties
Clone	17B4
Isotype	Mouse IgG1κ
Source/Host	Purified from concentrated hybridoma tissue culture supernatant.
Immunogen/Antigen	Synthetic peptide corresponding to 30 aa in the N-terminus of human LAG-3.
Label/Conjugates	ATTO 590
Application	Immunocytochemistry
Crossreactivity	Human
Specificity	Recognizes human LAG-3.
Purity	≥95% (SDS-PAGE)
Purity Detail	Protein G-affinity purified.
Concentration	0.5mg/ml
Formulation	Liquid. In PBS containing 0.02% sodium azide.
Isotype Negative Control	Mouse IgG1 Isotype Control
Other Product Data	New ATTO-fluorescent antibodies show increased photostability, outstanding brightness and intense signals. ATTO dyes are thermally stable, resistant to environmental changes and show no significant isomerization. ATTO 590 shows bright red fluorescence (λabs (max): 594nm, λem (max): 624nm, εmax: 120’000).
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	+4°C
Handling Advice	Do not freeze. Protect from light.
Use/Stability	Keep conjugated formats at +4°C. Stable for at least 1 year after receipt when stored at +4°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product-specific References

Description

Lymphocyte activation gene 3 (LAG-3; CD223) plays an important role in negatively regulating T cell proliferation, function and homeostasis. It is required for maximal natural and induced regulatory T cell (Treg) function. LAG-3 is closely related to the T cell co-receptor CD4 and binds to MHC class II molecules but with a significantly higher affinity than CD4.

Product References

Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens: E. Baixeras, et al.; J. Exp. Med.176, 327 (1992)
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand: B. Huard, et al.; Immunogenetics 39, 213 (1994)
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein: B. Huard, et al.; PNAS 94, 5744 (1997)
CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling: S. Hannier, et al.; J. Immunol. 161, 4058 (1998)
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts: C.E. Demeure, et al.; Eur. J. Cancer 37, 1709 (2001)
Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway: E.D. Carlo, et al.; J. Pathol. 205, 82 (2005)
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells: L. Macon-Lemaitre and F. Triebel; Immunology 115,170 (2005)
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors: F. Triebel, et al.; Cancer Lett. 235, 147 (2006)
Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells: J. Bayry, et al.; J. Immunol. 178, 4184 (2007)
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation: C. Casati, et al.; J. Immunol. 180, 3782 (2008)

Call	+41 61 926 6040
Fax	+41 61 926 6049